Asep Medical Holdings Inc. Achieves Significant Milestones Addressing Antibiotic Failure Through Proprietary Diagnostic and Treatment Technologies

VANCOUVER, BC, December 23, 2022 /PRNewswire/ – Asep Medical Holdings Inc. (“Asep Inc.” or the “Agency”) (CSE: ASEP) (OTCQB: SEPSF) (FSE: JJ8) is pleased to announce that, through its subsidiaries Sepset Biosciences Inc. (“Sepset“) and ABT Innovations Inc. (“ABT”), the company is addressing antibiotic failure on two fronts: a new diagnostic test that detects severe sepsis in the emergency room (ER), and a peptide technology that fights hard-to-treat infections known as biofilms.

Logo Asep Medical Holdings Inc. (CNW Group/ASEP Medical Holdings Inc.)

Logo Asep Medical Holdings Inc. (CNW Group/ASEP Medical Holdings Inc.)

Antibiotic failure is generally referred to as any situation where the bacteria survives antibiotic treatment and the clinical symptoms of the infection persist1. With around 47-50 million cases of sepsis annually worldwide2 and more than 11 million dead, faster and more accurate detection of sepsis will save lives. Additionally, there are currently no approved treatments for biofilm infections, which is alarming from 65%3 of all infections are biofilms.

The diagnostic technology of Asep Inc., SepsetERTM, is a blood-based gene expression test that can provide early and accurate diagnosis of severe incidences of the deadly disease sepsis. SepsetE.R provides results between 60 and 90 minutes while conventional diagnostic tools can take about 8 – 36 hours. Early diagnosis of sepsis along with timely and appropriate treatments increases the likelihood of survival for patients4 significantly.

In addition to accelerating the sepsis detection process, Asep Inc. also offers a patented peptide technology that targets and suppresses biofilm regrowth and reduces inflammation, addressing the ineffectiveness of current treatments for a wide range of difficult-to-treat infections . The technology covers a wide range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ENT, sinus, orthopedic, etc.), anti-inflammatories, immunomodulators, anti-infectives and vaccine adjuvants. This opens up a number of different potential avenues for revenue generation for this breakthrough technology.

To date, the Company and its subsidiaries have received over $20 million in non-dilutive grants from organizations such as the Bill & Melinda Gates Foundation, Genome Canada and the University of British Columbia. The company, through its preclinical partner iFyber LLC, has also received funding from the US Army for its new antibiofilm peptide technology.

Asep is addressing an unmet need in healthcare, which affects 49 million people a year. Having developed two new revolutionary technologies to diagnose sepsis and treat biofilm infection, the potential market opportunity for this company is huge as hospitals and clinics around the world could be online to treat their patients using these technologies cutting edge”, said Dr. Robert EW Hancockfounder, president and CEO of Asep Inc.

ABOUT ASEP MEDICAL HOLDINGS INC.

Asep Medical Inc. (asepmedical.com) is dedicated to addressing the failure of antibiotics by developing new solutions for important unmet medical needs. The Company is a consolidation of two existing privately held companies (Sepset Biosciences Inc. and ABT Innovations Inc.) who are both in the advanced development of both proprietary diagnostic tools, enabling early and timely identification of severe sepsis and broad spectrum therapeutic agents for address multidrug-resistant biofilm infections.

Sepset Biosciences Inc. (sepset.ca) is developing a diagnostic technology involving a patient’s gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure as antibiotics are the primary treatment for sepsis . Despite this, sepsis is responsible for almost 20% of all deaths on the planet. The SepsetE.R test is a blood-based gene expression test that is simple to implement and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in that it allows for the diagnosis of severe sepsis within 1-2 hours of the first clinical presentation (for example, in the emergency room), while other diagnostics provide the diagnosis only after 24-36 hours. Asep Inc. believes this will enable clinicians to make timely and critical decisions regarding appropriate therapies and reduce overall morbidity and mortality from sepsis.

ABT Innovations Inc.’s (abtinnovations.ca) peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections (medical device infections, chronic infections, lung, bladder, wound, dental, skin, ear- nose and throat, sinusitis, orthopedics, etc.), anti-inflammatories, anti-infective immunomodulators and vaccine adjuvants. The company is in the preclinical development stage with promising data.

FORWARD-LOOKING STATEMENTS –

This press release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are often characterized by words such as “expects”, “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “expects”, “estimates”, “may,” ” will”, “potential”, “proposed”, “positioned” and other similar words, or claims that certain events or conditions “may” or “will occur”. These statements include, but are not limited to, the success of clinical trials of our sepsis diagnostic test and its filing for regulatory approval; and initiating preclinical studies of our lead therapy, with the expectation that this will lead to rapid clinical trials. Various assumptions have been used in drawing conclusions or making the predictions contained in the forward-looking statements in this press release. Forward-looking statements are based on management’s opinions and estimates as of the date they are made and are subject to a variety of risks (including those risk factors identified in Asep Medical Inc.’s prospectus dated November 9, 2021) available for review from a Company profile at www.sedar.com and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Asep Medical Inc. has no obligation, and expressly disclaims any intent or obligation, to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

_________________________

1 https://www.frontiersin.org/articles/10.3389/fddsv.2022.892975/full#:~:text=Antibiotic%20failure%20can%20be%20defined%20as%20any%20situation%20where%20bacteria,symptoms%20of%20the %20infection%20 persist.

2 https://www.global-sepsis-alliance.org/sepsis

3 https://www.sciencedirect.com/science/article/pii/S1726490117302587

4 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304323/#:~:text=However%2C%20detection%20early%20of%20sepsis and%20a%20reduction%20of%20mortality.

cision

cision

View original content to download media: https://www.prnewswire.com/news-releases/asep-medical-holdings-inc-achieves-significant-milestones-addressing-antibiotic-failure-through-proprietary-diagnostic- -therapeutic-technologies-301709775.html

SOURCE ASEP Medical Holdings Inc.

Add a Comment

Your email address will not be published. Required fields are marked *